HUE032430T2 - Kristályos tripeptid epoxiketon proteáz inhibitorok - Google Patents

Kristályos tripeptid epoxiketon proteáz inhibitorok Download PDF

Info

Publication number
HUE032430T2
HUE032430T2 HUE14178725A HUE14178725A HUE032430T2 HU E032430 T2 HUE032430 T2 HU E032430T2 HU E14178725 A HUE14178725 A HU E14178725A HU E14178725 A HUE14178725 A HU E14178725A HU E032430 T2 HUE032430 T2 HU E032430T2
Authority
HU
Hungary
Prior art keywords
compound
pharmaceutical composition
treatment
disease
cell
Prior art date
Application number
HUE14178725A
Other languages
English (en)
Inventor
Pasit Phiasivongsa
Louis C Sehl
Original Assignee
Onyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42738216&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE032430(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Onyx Therapeutics Inc filed Critical Onyx Therapeutics Inc
Publication of HUE032430T2 publication Critical patent/HUE032430T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/026—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution by fragment condensation in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)

Claims (6)

  1. Kristályos tripeptki epozlkelőn proteàz Inhibitorok Szabadalmi igénypontok ' svésznonm' u\. \ lu s ^ \ ίο f diójukat·, >otd</í
    (II) xepkiü szerkezettel rendelkező kristályos vegyületet laríalttiaz. i.: áig: I í liÉ^pdf §zkíldÍ jyfgpsistl ilÉ^dmlpy:, aki &amp; készítmény egy orálisan adagolható készitmcny, 3. A 2, igénypont szerinti gyógyászatk&amp;ifteény, ahol az orillfc Maiolhatd MMltmépk egy tabletta, egy kapszula, egy granulátum, egy por és egy- szirup közül választóit. 4 A 5 meny pont »/eonu gu\A e.zu k vUn.oa. «λΊ '·> mahvm adapó un* koszán u "< egy tabletta, k A ä. Igénypont laerltút jyliyl^^l imksp gklÉ^ egy kapszula. o. a 3. igénypont szédüli gyógyászati kce/itmtay, Äul:l^#tiIiÄ:äi|pliÄ* Í#fteá#öf egy granulálom ?. A szerinti gyógyászati készítmény. ahol az orálisan adagolható készítmény egy por..
  2. 8, Az 1. igéttyppm szerinti gyógyászati készítmény, ahol a készitméay egy parenierálísan adagolható készítmény. '} V 1 Ó mcmp. mok 'tfs'v Ok. \o\au g.. ;. N omu no sus s ki a kristályos vegyü lei Ói k'tOK'5 U" p.WU/O \ví 1L MtOi ' '10 0 ' '.«ΠΟ'Ί“ l OUVk"'* í WC\! O. "u tat. ÎÜK Az. 1-9 igénypontok bármelyike szerinti gyógyászati kcszttmém.. ahol a ka} képiéit* szerkezettel rendelkező kristályos vegyidet (u) - 03 tömeg% tömegvesztóÉ: mutat z5°C « ioS^C hőmérséklettartományban végzett termogmvtmetriás analízisben t k Az 1-10. igénypontok bármelyike szerinti gyógyászati készítmény rák kezelésében történő alkalmazásra:. 1 ? \ gup. uWau kés mmeu\ a 11 g.unpom s/vnou atkahnazasta, ahol a otk <í hohen vet esőm. agy. mell móhmak, mellkas, sastaghól. eytviometriom. nyelőcső, szem. faj. vese. máj. ttün. nvnokcsotnok. va . nyak. f\míA ck. lur.n\<}dn.ngs ptosrtata. hete. torok vagy a vb rákja. la .ár ló igknvp!.'".k'k barmo'.k.ï, vésőm cvogs aszal· kwstsnue kezeLsabes-. nmen-' alkalmazásra leukémia, akut Hmíbehás kuké-tnia (ALL), akut mkdogén leukémia tAML}. krónikus limtbcitás leukémia COLL). krónikus-míelogé«'leukémia (CMi), szdrsejt lenkénti%:| kis km locals Hmíótna, ly mphop 1 asm acyt i c « s limloma. plazma sejt mielóma, plasmocytome vagy összetett nueléms kezelésében történő alkalmazásra '4 b. -Ό 'gvoyom \ m "οΙμ^'ν .. *. ogvav.m kev a nesw összetett tmeiomn kezelésében történő trtkálmaiáirá; l.\ \í Mtt igcíV|Ka.\'k hnmehske sze-ism «*·., u ees.uonvuyAkakíenslrom ntukroglobuhnemtit kvzckvben totteno alkalmazásra igény pontok Mnfcá'f ike szerinti gyógyászán készítmény vgv bematologiât Á kok, Wakiensnnm m&amp;kreg!obairtömia. <Ka*eten mtelfom, diifàz B sejt Hmlömtk köpggpgff '' ^ t» i ö N ' » Ά> Mé k *v \,\C „.o ,vs H CA-h \"> Woero mmtimazásta. '"' \. M*'; ge^pomAKumeHu - vemm gyáván ke*znmen> m^utsszpamas s/imf roma vagy mieloproliíetmiv betegség kezelésében történő alkalmazásra. jlx Àe I- Hl igénypontok báímdpkg szerinti gyógyászati készítmény egy ggioimmun betegség kezelésében történő alkalmazásra. It, Ä gyógy ászán készítmény a lók igénypont szerinti ,tikattöazis% öltői az autoimmun bc-#ggfii|pp«% rbgnnmtöid arthritis, es ammon képzés kézéi kuntf ke '20. Az 1 -10. igénypontok bármelyike ..szerinti gyógyászán készítmény egy gstâtai vagy transzplanuitum mai összefüggő álkgnnkezetesében tőrté'nö"8itelr»azásra.
  3. 21. A gyógyászati yszlMéhy as|p. igénypont szeri mi alkalmazásra, ahol agraiüái vagy tjansplantátumptal 5sszeli|g0 állapot gmfezezsus hóit betegség,
  4. 22, Az i-fCi igényperek hinnelyíke szerinti gyógyászati készítmény égy pepmófgeneratiy betegség kezelésében történő alkalmazik II, Az MI, igénypontok bármelyike szerinti gyógyászati készítmény gyullanáskezdésében történő alkalmazásra,
  5. 24. Az Idík Igibypmitök bártrtelyike szerimi gyógyászati készítmény egy ilbrózíssgl összefüggő állagolkezdésében történő alkalmazásra. A \z M0 igénypontéi' bm melyike vénán gyngymumri készítmény egy i se he műn d oevo-függő ál tagot kezelésében történő alkalmazásra,
  6. 26- A gyógyászati készítmény a '' s,. igénypont gzerttiisalkiIbtöÄas ahol az. isdierniávat ösz-szduggő állapot szivelégtelénalg. 2?', Az ! - 10. lgén>ponUik ban-nehsHe seennu gyi>gyá:>/«u késdimány egy íertöpg kezdésé-bén ujrtéeg alkamwisrn. 21, Ä2 1 - ! 0. sgyblti gybgyásgab késdgrdoy egy cson!vcv/tdae! járé betegség fezeiesáben. tári&amp;é élkáteáMim,· 22, ,4 gyégyászgíl készffméiw g 21. igenypoíu szerinti ahg! a csöMkemtéssei járó betegaégosteöpörbsls,
HUE14178725A 2009-03-20 2010-03-22 Kristályos tripeptid epoxiketon proteáz inhibitorok HUE032430T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16219609P 2009-03-20 2009-03-20
US18056109P 2009-05-22 2009-05-22

Publications (1)

Publication Number Publication Date
HUE032430T2 true HUE032430T2 (hu) 2017-09-28

Family

ID=42738216

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14178725A HUE032430T2 (hu) 2009-03-20 2010-03-22 Kristályos tripeptid epoxiketon proteáz inhibitorok

Country Status (45)

Country Link
US (5) US20100240903A1 (hu)
EP (2) EP2813241B1 (hu)
JP (1) JP5723357B2 (hu)
KR (1) KR101729344B1 (hu)
CN (1) CN102428075B (hu)
AP (1) AP3513A (hu)
AR (1) AR075899A1 (hu)
AU (1) AU2010226410B2 (hu)
BR (1) BRPI1009369A2 (hu)
CA (1) CA2755971C (hu)
CL (1) CL2011002326A1 (hu)
CO (1) CO6430433A2 (hu)
CR (1) CR20110491A (hu)
CU (1) CU20110176A7 (hu)
CY (1) CY1118359T1 (hu)
DK (2) DK2813241T3 (hu)
DO (1) DOP2011000286A (hu)
EA (2) EA024672B1 (hu)
EC (1) ECSP11011341A (hu)
ES (2) ES2527619T3 (hu)
GE (1) GEP20156392B (hu)
HK (2) HK1162476A1 (hu)
HN (1) HN2011002459A (hu)
HR (2) HRP20150014T1 (hu)
HU (1) HUE032430T2 (hu)
IL (1) IL215174A (hu)
LT (1) LT2813241T (hu)
MA (1) MA33197B1 (hu)
ME (1) ME01277B (hu)
MX (2) MX343562B (hu)
MY (1) MY156522A (hu)
NI (1) NI201100170A (hu)
NZ (2) NZ618432A (hu)
PE (1) PE20120645A1 (hu)
PL (2) PL2408758T3 (hu)
PT (2) PT2408758E (hu)
RS (2) RS53746B1 (hu)
SA (2) SA110310221B1 (hu)
SG (2) SG2014011373A (hu)
SI (2) SI2408758T1 (hu)
SM (2) SMT201500009B (hu)
TN (1) TN2011000470A1 (hu)
TW (1) TWI504598B (hu)
WO (1) WO2010108172A1 (hu)
ZA (2) ZA201106826B (hu)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1948678T3 (pl) 2005-11-09 2013-09-30 Onyx Therapeutics Inc Związki do hamowania enzymów
DK2041158T3 (da) 2006-06-19 2013-06-24 Onyx Therapeutics Inc Peptid-epoxidketoner til proteasom inhibering
KR20150131405A (ko) 2007-10-04 2015-11-24 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
EP2349313A4 (en) 2008-10-21 2012-08-29 Onyx Therapeutics Inc COMBINATION THERAPY WITH EPOXYCLETON PEPTIDES
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
EP3153020B1 (en) 2009-10-07 2018-11-28 Dow AgroSciences LLC Synergistic fungicidial mixtures for fungal control in cereals
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
MX2012010017A (es) 2010-03-01 2012-10-01 Onyx Therapeutics Inc Compuestos de para la inhibicion de inmunoproteasomas.
CN102946729B (zh) 2010-04-07 2014-11-05 欧尼斯治疗公司 结晶肽环氧酮免疫蛋白酶体抑制剂
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
EP2883960B1 (en) * 2012-08-10 2020-05-13 Ajinomoto Co., Inc. METHOD FOR PRODUCING gamma-GLUTAMYL-VALYL-GLYCINE CRYSTAL
TW201422255A (zh) * 2012-10-24 2014-06-16 Onyx Therapeutics Inc 用於蛋白酶體抑制劑之調整釋放製劑
ES2666144T3 (es) 2012-12-28 2018-05-03 Dow Agrosciences Llc Mezclas fungicidas sinérgicas para control fúngico en cereales
US9549556B2 (en) 2013-12-26 2017-01-24 Dow Agrosciences Llc Macrocyclic picolinamides as fungicides
CN104945470B (zh) * 2014-03-30 2020-08-11 浙江大学 杂环构建的三肽环氧酮类化合物及制备和应用
CN104974221B (zh) * 2014-04-03 2020-10-23 中国医学科学院药物研究所 二肽及三肽类蛋白酶体抑制剂及其制法和药物用途
EP3166936A4 (en) 2014-07-08 2017-11-22 Dow AgroSciences LLC Macrocyclic picolinamides as fungicides
US20160115198A1 (en) 2014-10-27 2016-04-28 Apicore Us Llc Methods of making carfilzomib and intermediates thereof
CA2972405A1 (en) 2014-12-30 2016-07-07 Dow Agrosciences Llc Use of picolinamide compounds as fungicides
RU2702697C2 (ru) 2014-12-30 2019-10-09 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Использование пиколинамидных соединений с фунгицидной активностью
AU2015374458B2 (en) 2014-12-30 2018-02-15 Dow Agrosciences Llc Use of picolinamide compounds with fungicidal activity
RU2703402C2 (ru) 2014-12-30 2019-10-16 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Пиколинамиды с фунгицидной активностью
WO2016109305A1 (en) 2014-12-30 2016-07-07 Dow Agrosciences Llc Use of picolinamides as fungicides
CN105949279A (zh) * 2016-04-27 2016-09-21 浙江大学 蛋白酶体抑制剂Oprozomib及其类似物的制备方法
KR102655020B1 (ko) 2016-06-29 2024-04-04 케자르 라이프 사이언스 펩티드 에폭시케톤 면역프로테아좀 억제제의 결정질 염
EA201990157A1 (ru) 2016-06-29 2019-05-31 Кезар Лайф Сайнсиз Способ получения пептидного эпоксикетонового ингибитора иммунопротеасомы и его предшественников
WO2018044996A1 (en) 2016-08-30 2018-03-08 Dow Agrosciences Llc Picolinamides as fungicides
WO2018045003A1 (en) 2016-08-30 2018-03-08 Dow Agrosciences Llc Picolinamide n-oxide compounds with fungicidal activity
US10231452B2 (en) 2016-08-30 2019-03-19 Dow Agrosciences Llc Thiopicolinamide compounds with fungicidal activity
US10334852B2 (en) 2016-08-30 2019-07-02 Dow Agrosciences Llc Pyrido-1,3-oxazine-2,4-dione compounds with fungicidal activity
WO2018057453A1 (en) 2016-09-21 2018-03-29 Amgen Inc. Immediate release formulations for oprozomib
JP2018123119A (ja) 2016-12-14 2018-08-09 アムジエン・インコーポレーテツド オプロゾミブのための胃内保持型の徐放性剤形、及びその調製プロセス
BR102018000183B1 (pt) 2017-01-05 2023-04-25 Dow Agrosciences Llc Picolinamidas, composição para controle de um patógeno fúngico, e método para controle e prevenção de um ataque por fungos em uma planta
EP3618626A4 (en) 2017-05-02 2020-12-02 Dow Agrosciences LLC USE OF AN ACYCLIC PICOLINAMIDE COMPOUND AS A FUNGICIDE FOR FUNGAL GRASS INFESTATION
TWI774761B (zh) 2017-05-02 2022-08-21 美商科迪華農業科技有限責任公司 用於穀物中的真菌防治之協同性混合物
TW201842851A (zh) 2017-05-02 2018-12-16 美商陶氏農業科學公司 用於穀類中的真菌防治之協同性混合物
CN111108125A (zh) 2017-09-14 2020-05-05 葛兰素史密斯克莱知识产权发展有限公司 用于癌症的组合治疗
BR102019004480B1 (pt) 2018-03-08 2023-03-28 Dow Agrosciences Llc Picolinamidas como fungicidas
CA3115684A1 (en) 2018-10-15 2020-04-23 Dow Agrosciences Llc Methods for sythesis of oxypicolinamides
CN118255835A (zh) * 2022-12-27 2024-06-28 上海美悦生物科技发展有限公司 三肽环氧酮化合物、药物组合物及其制备方法和用途

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5135919A (en) 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
US5441944A (en) 1989-04-23 1995-08-15 The Trustees Of The University Of Pennsylvania Substituted cyclodextrin sulfates and their uses as growth modulating agents
US5071957A (en) 1989-08-04 1991-12-10 Bristol-Myers Company Antibiotic BU-4061T
US4990448A (en) 1989-08-04 1991-02-05 Bristol-Myers Company Bu-4061T
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
IL97428A0 (en) 1990-03-05 1992-06-21 Cephalon Inc Chymotrypsin-like proteases and their inhibitors
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
US5340736A (en) 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
ATE195553T1 (de) * 1992-06-09 2000-09-15 Chiron Corp Kristallisierung von m-csf
GB9300048D0 (en) 1993-01-04 1993-03-03 Wellcome Found Endothelin converting enzyme inhibitors
TW380137B (en) 1994-03-04 2000-01-21 Merck & Co Inc Process for making an epoxide
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US6506876B1 (en) 1994-10-11 2003-01-14 G.D. Searle & Co. LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
DE19505263A1 (de) 1995-02-16 1996-08-22 Consortium Elektrochem Ind Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US6150415A (en) 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith
WO1998010779A1 (en) 1996-09-13 1998-03-19 New York University Method for treating parasitic diseases with proteasome inhibitors
EP2409985A3 (en) 1996-10-18 2013-05-01 Vertex Pharmaceuticals Incorporated Inhibitors de serine proteases, especially of the NS3 protease of the hepatitis C virus
SI0932617T1 (en) 1996-10-18 2002-06-30 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
DE69819721T2 (de) 1997-06-13 2004-09-23 Cydex Inc., Overland Park Zusammensetzung mit erhöhter lagerstabilität enthaltend cyclodextrin und wirkstoffe oder wirkstoff-vorstufen, die in wasserunlösliche komponenten zersetzt werden
US6133308A (en) 1997-08-15 2000-10-17 Millennium Pharmaceuticals, Inc. Synthesis of clasto-lactacystin beta-lactone and analogs thereof
US6100282A (en) * 1998-01-02 2000-08-08 Hoffman-La Roche Inc. Thiazole derivatives
US6075150A (en) 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
US6099851A (en) 1998-06-02 2000-08-08 Weisman; Kenneth M. Therapeutic uses of leuprolide acetate
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6838436B1 (en) 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6902721B1 (en) 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
BR9914648A (pt) 1998-10-20 2001-11-27 Millennium Pharm Inc Processo para monitorar ação medicamentosa deinibidor de proteasoma
US6492333B1 (en) 1999-04-09 2002-12-10 Osteoscreen, Inc. Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
US6831099B1 (en) 1999-05-12 2004-12-14 Yale University Enzyme inhibition
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
WO2001028579A2 (en) 1999-10-20 2001-04-26 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone and hair growth
DE50110956D1 (de) 2000-10-12 2006-10-19 Viromics Gmbh Proteasome inhibitoren zur behandlung von hepatitis-virus infektionen
GB0114185D0 (en) * 2001-06-12 2001-08-01 Protherics Molecular Design Lt Compounds
CA2435146C (en) 2001-01-25 2011-03-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Formulation of boronic acid compounds
DK1392355T3 (da) 2001-05-21 2007-04-30 Alcon Inc Anvendelse af proteasominhibitorer tilbehandling af öjentörhedslidelser
AU2003219652A1 (en) 2002-01-08 2003-07-30 Eisai Co. Ltd. Eponemycin and epoxomicin analogs and uses thereof
US20040116329A1 (en) 2002-01-29 2004-06-17 Epstein Stephen E. Inhibition of proteasomes to prevent restenosis
CA2481306A1 (en) 2002-04-09 2003-10-23 Greenville Hospital System Metastasis modulating activity of highly sulfated oligosaccharides
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20030224469A1 (en) 2002-06-03 2003-12-04 Buchholz Tonia J. Methods and kits for assays utilizing fluorescence polarization
US7902185B2 (en) 2002-06-03 2011-03-08 Als Therapy Development Foundation, Inc. Treatment of neurodegenerative diseases using proteasome modulators
AU2003256847A1 (en) 2002-07-26 2004-02-16 Advanced Research And Technology Institute At Indiana University Method of treating cancer
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
TW200418791A (en) 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
PE20130200A1 (es) 2003-04-08 2013-03-09 Novartis Ag Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar
WO2005004798A2 (en) 2003-06-10 2005-01-20 The J. David Gladstone Institutes Methods for treating lentivirus infections
US7012063B2 (en) 2003-06-13 2006-03-14 Children's Medical Center Corporation Reducing axon degeneration with proteasome inhibitors
NZ548225A (en) 2003-12-31 2012-12-21 Cydex Pharmaceuticals Inc Inhalant formulation containing sulfoakyl ether cyclodextrin and corticosteroid
GB0400804D0 (en) 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
US20050228031A1 (en) * 2004-04-13 2005-10-13 Bilodeau Mark T Tyrosine kinase inhibitors
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
CN102174076A (zh) 2004-04-15 2011-09-07 普罗特奥里克斯公司 用于抑制蛋白酶体酶的化合物
WO2005111009A2 (en) 2004-05-10 2005-11-24 Proteolix, Inc. Synthesis of amino acid keto-epoxides
DK2030981T3 (da) 2004-05-10 2014-10-13 Onyx Therapeutics Inc Forbindelser til proteasom-enzymhæmning
CN101044157B (zh) * 2004-08-06 2011-07-13 普罗特奥里克斯公司 用于抑制蛋白酶体的化合物
AU2005295183A1 (en) 2004-10-20 2006-04-27 CAOnyx Therapeutics, Inc. Labeled compounds for proteasome inhibition
DK1819353T3 (da) 2004-12-07 2011-05-16 Proteolix Inc Sammensætning til proteasomhæmning
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7589066B2 (en) 2005-03-11 2009-09-15 The University Of North Carolina At Chapel Hill Potent and specific immunoproteasome inhibitors
EP1876893B1 (en) 2005-04-15 2012-04-11 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
PL1948678T3 (pl) 2005-11-09 2013-09-30 Onyx Therapeutics Inc Związki do hamowania enzymów
AR057227A1 (es) 2005-12-09 2007-11-21 Centocor Inc Metodo para usar antagonistas de il6 con inhibidores del proteasoma
US20070207950A1 (en) 2005-12-21 2007-09-06 Duke University Methods and compositions for regulating HDAC6 activity
WO2007122686A1 (ja) 2006-04-14 2007-11-01 Eisai R & D Management Co., Ltd. ベンズイミダゾール化合物
DE102006026464A1 (de) 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
DK2041158T3 (da) 2006-06-19 2013-06-24 Onyx Therapeutics Inc Peptid-epoxidketoner til proteasom inhibering
WO2008033807A2 (en) 2006-09-13 2008-03-20 The Arizona Board Of Regents On Behalf Of The University Of Arizona Synergistic combinations of antineoplastic thiol-binding mitochondrial oxidants and antineoplastic proteasome inhibitors for the treatment of cancer
US8601054B2 (en) * 2006-12-07 2013-12-03 International Business Machines Corporation Project-related communications
CA2676387A1 (en) 2007-01-23 2008-07-31 Gloucester Pharmaceuticals, Inc. Combination therapy
WO2008140782A2 (en) * 2007-05-10 2008-11-20 Proteolix, Inc. Compounds for enzyme inhibition
KR20150010802A (ko) 2007-08-06 2015-01-28 밀레니엄 파머슈티컬스 인코퍼레이티드 프로테아좀 억제제
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
KR20150131405A (ko) * 2007-10-04 2015-11-24 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
US7838673B2 (en) 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
JP5600595B2 (ja) 2007-10-16 2014-10-01 ミレニアム ファーマシューティカルズ， インコーポレイテッド プロテアソーム阻害剤
US20090131367A1 (en) 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
KR101690571B1 (ko) 2008-06-17 2016-12-28 밀레니엄 파머슈티컬스 인코퍼레이티드 보로네이트 에스테르 화합물 및 이의 제약학적 조성물
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
EP2349313A4 (en) 2008-10-21 2012-08-29 Onyx Therapeutics Inc COMBINATION THERAPY WITH EPOXYCLETON PEPTIDES
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
CN101928329B (zh) 2009-06-19 2013-07-17 北京大学 三肽硼酸(酯)类化合物、其制备方法和应用
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
MX2012010017A (es) 2010-03-01 2012-10-01 Onyx Therapeutics Inc Compuestos de para la inhibicion de inmunoproteasomas.
CN102892291A (zh) 2010-03-31 2013-01-23 米伦纽姆医药公司 1-氨基-2-环丙基乙硼酸衍生物
CN102946729B (zh) 2010-04-07 2014-11-05 欧尼斯治疗公司 结晶肽环氧酮免疫蛋白酶体抑制剂

Also Published As

Publication number Publication date
RS55431B1 (sr) 2017-04-28
AU2010226410A1 (en) 2011-11-03
EP2813241A1 (en) 2014-12-17
US20150175656A1 (en) 2015-06-25
EA024672B1 (ru) 2016-10-31
MY156522A (en) 2016-02-26
JP2012521363A (ja) 2012-09-13
SI2813241T1 (sl) 2017-03-31
PT2408758E (pt) 2014-11-04
HRP20161654T1 (hr) 2017-01-27
MX343562B (es) 2016-11-09
ME01277B (me) 2010-03-22
NZ618432A (en) 2015-04-24
SMT201700068B (it) 2017-03-08
CR20110491A (es) 2012-01-19
CL2011002326A1 (es) 2012-03-23
HRP20150014T1 (hr) 2015-02-27
AR075899A1 (es) 2011-05-04
RS53746B1 (en) 2015-06-30
CA2755971A1 (en) 2010-09-23
WO2010108172A1 (en) 2010-09-23
SI2408758T1 (sl) 2015-01-30
US8604215B2 (en) 2013-12-10
US20100240903A1 (en) 2010-09-23
CN102428075B (zh) 2016-05-11
PL2813241T3 (pl) 2017-04-28
CO6430433A2 (es) 2012-04-30
CU20110176A7 (es) 2012-04-15
GEP20156392B (en) 2015-11-10
SA110310221B1 (ar) 2014-04-28
CA2755971C (en) 2017-05-16
KR20110132577A (ko) 2011-12-08
SG2014011373A (en) 2014-05-29
ZA201106826B (en) 2018-11-28
SMT201500009B (it) 2015-03-05
AP2013007137A0 (en) 2013-09-30
EA201171151A1 (ru) 2012-04-30
DK2408758T3 (da) 2014-12-01
EP2813241B1 (en) 2016-11-16
HN2011002459A (es) 2015-03-16
EA201300860A1 (ru) 2014-04-30
AP3513A (en) 2016-01-05
NZ595847A (en) 2013-12-20
CN102428075A (zh) 2012-04-25
US8822512B2 (en) 2014-09-02
MX2011009777A (es) 2011-10-17
US9051353B2 (en) 2015-06-09
DK2813241T3 (en) 2017-01-16
TWI504598B (zh) 2015-10-21
SA114350283B1 (ar) 2016-06-08
JP5723357B2 (ja) 2015-05-27
EA020973B1 (ru) 2015-03-31
PT2813241T (pt) 2016-12-23
PE20120645A1 (es) 2012-06-07
TN2011000470A1 (en) 2013-03-27
HK1204952A1 (en) 2015-12-11
AU2010226410B2 (en) 2015-09-17
BRPI1009369A2 (pt) 2016-10-11
EP2408758A1 (en) 2012-01-25
SG174446A1 (en) 2011-10-28
ZA201601686B (en) 2016-11-30
DOP2011000286A (es) 2011-10-15
KR101729344B1 (ko) 2017-04-21
IL215174A (en) 2016-03-31
IL215174A0 (en) 2011-12-29
CY1118359T1 (el) 2017-06-28
US20140024804A1 (en) 2014-01-23
EP2408758B1 (en) 2014-10-22
ECSP11011341A (es) 2011-10-31
EP2408758A4 (en) 2012-09-05
PL2408758T3 (pl) 2015-03-31
HK1162476A1 (en) 2012-08-31
ES2527619T3 (es) 2015-01-27
US9403868B2 (en) 2016-08-02
LT2813241T (lt) 2017-01-10
NI201100170A (es) 2012-02-21
MA33197B1 (fr) 2012-04-02
US20120088903A1 (en) 2012-04-12
US20120077855A1 (en) 2012-03-29
TW201043623A (en) 2010-12-16
ES2614557T3 (es) 2017-05-31

Similar Documents

Publication Publication Date Title
DK2813241T3 (en) Crystalline tripeptide epoxy-ketone protease inhibitors
CA2701778C (en) Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
AU2013203857B2 (en) Crystalline tripeptide epoxy ketone protease inhibitors
AU2013203566B2 (en) Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides